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Abstract. We studied the effects of a single intravenous in- 
jection of rabbit ATG (RIVM, Bilthoven, The Nether- 
lands) in a dose of 8 mg/kg body weight administered 6 h 
after kidney transplantation on graft survival, rejection 
incidence, T-cell subsets, and cost-effectiveness. A total of 
58 (37 male/21 female) consecutive renal allograft reci- 
pients were entered in this trial. Treatment results were 
compared with 56 patients treated with intravenous cy- 
closporin (CyA). In all patients concomitant medication 
consisted of steroids and azathioprine, followed by oral 
CyA. Following rabbit ATG, T cells (WT31) quickly dis- 
appeared from the peripheral blood and a return to 
greater than lOO/mm' was observed at a median of 7 
(range 3-21) days. Graft survival was the same in both 
groups, as was the incidence of primary nonfunction. The 
rate of acute rejection was significantly lower in the rabbit 
ATG-treated patients (12% vs 50%). We conclude that a 
single shot of rabbit ATG is an attractive, easy, and cost- 
effective induction scheme with a low incidence of de- 
layed graft function and acute rejection episodes. A rela- 
tively high incidence of vascular thrombosis of the graft, 
however, warrants further study before this treatment 
regimen can be generally applied. 
Key words: Kidney transplantation, ATG - ATG, single 
shot, kidney transplantation - Rejection, single shot ATG 
- Single shot ATG, kidney transplantation 
Introduction 
Heterologous immunoglobulins to lymphocytes (ALG) 
or to thymocytes (ATG) are frequently used in organ 
transplantation as prophylaxis and treatment for acute 
graft rejection [5-71. In order to minimize cyclosporin 
(CyA) effects directly following transplantation, ALG, 
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ATG, or monoclonal OKT3 can be given in sequential 
treatment schedules. Using this strategy, several authors 
have reported a decrease in the incidence of delayed graft 
function in renal transplantation [6, 71. In these reports 
treatment was usually continued for 7-10 days after trans- 
plantation. Prolonged treatment with polyclonal immu- 
noglobulins requires an indwelling central venous ca- 
theter, which frequently leads to catheter-related sepsis 
[1]. Furthermore, this treatment is expensive, costing ap- 
proximately $4000 for a 10-day course. Treatment with 
OKT3, at a comparable price, is associated with a high fre- 
quency of side effects [3,8]. 
In an attempt to devise a safe, easy, and cost-effective 
sequential immunosuppressive protocol with a minimum 
of side effects, we studied the effect of a single, intrave- 
nous, high dose of rabbit ATG (r-ATG), administered 6 h 
after kidney transplantation, on graft survival, rejection 
incidence, total rabbit and specific rabbit anti-T-cell plas- 
ma immunoglobulin levels, as well as the effect on T cells 
in the peripheral blood. 
Materials and methods 
Study population 
The patient group consisted of 37 male and 21 female subjects. Only 
recipients of cadaveric donor organs were included. The mean age 
was 49.7years (range 18-73years). The mean number of mis- 
matches for HLA-ABDR was 1.9 ? 1.3, The current panel-reactive 
lymphocytotoxic antibody level was over 80% in three patients. The 
median cold ischemia time was 29 h 30 min (range 1 6 4 6  h) with a 
median second warm ischemia time of 29 min (1245 min). The me- 
dian follow-up period was 13 months. Controls consisted of 56 con- 
secutive patients who were transplanted just prior to this feasibility 
study and who did not receive T-cell-directed immunoglobulin pro- 
phylaxis apart from cyclosporin A (CyA). All patients were trans- 
planted at our center during a 3-year period. The clinical charac- 
teristics of both groups are shown in Table 1. Whenever acute rejec- 
tion was clinically suspected, a renal biopsy was performed. Only 
biopsy-proven rejections were analyzed. In order to allow a direct 
comparison of both groups, only rejection rates in the first 3 months 
after transplantation are given. 
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Table 1. Clinical patient characteristics 
Patient group CyA-treated r-ATG-treated P value 
(n = 5 6 )  (n - 5 8 )  
Age (years) 
Sex (mif) 
ABDR-mismatches 
Median ischemia times 
Cold ischemia (hours) 
First warm ischemia 
(min) 
Second warm ischemia 
(min) 
Diabetes 
Rctransplantation 
PRA >SO% 
42.8 % 13.6 
25131 
2.2 k 1.3 
2 (4%) 
26.5 (1344) 
0 (0-30) 
29 (1665) 
2 (4%) 
19 (34%) 
48.4k 16.8 NS 
37/12 NS 
1.9 k 1.3 NS 
3 (5  Yo) NS 
29.3 (1.546) NS 
0 (0-1 0) NS 
24 (12-46) NS 
4 (7 Yo) NS 
13 (22%) NS 
Treatment protocol 
r-ATG groz~p.  All patients received 8 mg/kg-r-ATG (RIVM, Bilt- 
hoven, The Netherlands [4]) 6 h post-transplantation, following ad- 
ministration of 50 mg methylprednisolone and 4 mg clemastine. 
CyA was started orally on day 5 at a dose of S mg/kg per day divided 
into two equal doses and was adjusted to obtain plasma trough levels 
of 50-75 ngiml. Concomitant immunosuppression consisted of aza- 
thioprine (1.5 mg/kg per day) for 5 days and 15 mg of prednisone. T 
cells were monitored on days 0,1,3,5,7, and 14 post-transplantation. 
CyA group. CyA was started intravenously at a dose of 2 mg/kg 6 h 
after anastomosis. From day 3 onwards, CyA was given orally 
(8 mgikg) in two doses and adjusted to plasma trough levels of 50- 
75 ng/ml. All patients received azathioprine (1.5 mgikg) for 5 days 
and 15 mg of prednisone. 
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Fig.1. Plasma levels of total r-ATG measured by ELISA (-0-) 
and specifically T-cell-directed r-ATG as measured by the HPB- 
ALL binding assay (-0-) after a single shot (8 mg/kg) of r-ATG 
Laboratory procedures 
In order to determine the number of circulating T cells, a two-color 
FACS analysis was performed. In brief, 100 p1 heparinized whole 
blood was incubated for 30 min with 20 p1 of a monoclonal antibody 
(mAb) combination conjugated directly to fluorescein isothio- 
cyanate (FITC) or phycoerythrin (PE). The mAb combinations 
used were: LeucoGATE (CD45/CD14), IgG,/IgG,, control and 
WT31/CD5 (Becton & Dickinson, Mountain View, Calif., USA). 
WT31 is directed against the alpchain of the T-cell receptor and was, 
therefore, used as a pan T-cell marker. Data were acquired on a 
FACScan using Simulset software (Becton & Dickenson) to estab- 
lish a lymphocyte analysis gate that included at least 95 YO of the lym- 
phocytes and that was contaminated by no more than 10% of mono- 
cytes, granulocytes, or debris. At least 2000 lymphocyte events were 
acquired from each tube. Total r-ATG plasma was measured using a 
sandwich ELISA method. Microtiter plates were coated with goat 
anti-rabbit IgG (Pierce, Rockford, Ill., USA). Following incubation 
with 0.1 ml samples of diluted plasma (1:200) or r-ATG (1- 
3000 ng/ml), bound rabbit IgG was estimated with alkaline phospha- 
tase-conjugated goat anti-rabbit IgG (Pierce). 
Specific r-ATG in plasma was determined in a cell-binding assay 
on a human tumor T-cell line (HPB-ALL). Plasma samples (diluted 
1:3, 1:10, and 1:30) or r-ATG (1:3.102-1:3.106) as reference were 
incubated with 5.10' HPB-ALL cells. After washing, FITC-con- 
jugated donkey anti-rabbit IgG (Pierce) was added and cells were 
analyzed by flow cytometry (FACScan) with logarithmic amplifica- 
tion of the fluorescence signal. Results were expressed in arbitrary 
units assuming there was 100 U/ml in the original batch of r-ATG. 
Statistical analysis 
The clinical characteristics of the two groups and the differences in 
treatment outcome between the r-ATG and control groups were 
compared using the unpaired t-test or chi-square test for2 x 2 tables 
where appropriate. Survival data were assessed using actuarial life- 
table analysis. Survival times were compared using the log-rank test. 
A P value less than 0.05 was considered significant in all tests. All 
data are expressed as mean k SD. 
Results 
The two treatment groups were highly comparable with 
regard to the distribution of sex, diabetes, retransplanta- 
tion, ischemia times, and the mean number of mismatches 
for the HLA-ABDR loci. 
Following treatment with r-ATG, we observed fever 
(temperature > 38 "C) and/or chills in 59 '%a (35/58) of the 
patients. No episodes of catheter-related sepsis, broncho- 
spasm, or hypotension were observed. Serum sickness was 
observed in four patients on days 8-15 after treatment; 
this responded rapidly to treatment with steroids. Urinary 
tract infection occurred in 27% (16/58) of the patients. 
Evidence of cytomegalovirus (CMV) disease, defined as 
fever over 38°C and seroconversion, was found in 8% 
(5158) of the patients, which was not different from that in 
the CyA group. 
Following the single dose, total r-ATG levels decreased 
with a plasma half-life of 7.2 days. Specific r-ATG de- 
creased much more rapidly with a plasma half-life of 
1.2 days for the first 3 days after transplantation and a 
half-life of 3.3 days during the subsequent period (Fig. 1). 
T cells (WT31) quickly disappeared from the circulation 
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Fig.2. Reappearance of circulating T cells after a single shot 
(8 mgikg) of r-ATG 
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Fig.3. Actuarial graft survival curve after renal transplantation in 
patients treated with cyclosporin with (-) or without (----) a single 
dose of rabbit ATG 
and a return to greater than 100/mm3 was observed at a 
median of 7 days (range 3-21 days; Fig.2). 
No difference in graft survival was found between the 
two treatment groups (Fig. 3). The incidence of primary 
nonfunction, defined as the need for dialysis treatment 
following transplantation, was 28 '30 (16/58) in the r-ATG- 
treated patients, which was comparable to that in the CyA 
group. When dividing transplants with primary nonfunc- 
tion into two groups, i. e., those that never functioned and 
had to be removed, and those functioning after a delay of 
several days or weeks, there was a tendency towards a 
lower frequency of delayed graft function and towards a 
higher number of never functioning grafts in the r-ATG 
groups, neither of which reached statistical significance. A 
total of seven grafts never functioned and were removed. 
Histological examination of these grafts following trans- 
plantectomy revealed vascular thrombosis and necrosis in 
three patients, one of whom had received two kidneys 
from a 3-year-old infant transplanted en bloc. In the other 
four patients with primary nonfunction, tubular damage 
and necrosis was observed, which could have been caused 
by either perfusion damage or vascular thrombosis. No 
immunoglobulin deposits suggestive of accelerated hu- 
moral rejection were found. 
The incidence of biopsy-proven acute rejection follow- 
ing r-ATG was 12 YO (7/58), which was lower than the re- 
jection rate in the CyA group ( P  < 0.05; Table 2). All re- 
jection episodes occurred more than 5 days after r-ATG 
treatment and were successfully treated with a 10-day 
course of the same r-ATG preparation in a dose of 4 mg/kg 
in four patients and 1000mg methylprednisolone on 3 
consecutive days in four patients. N o  correlation was ob- 
served between the occurrence of rejection and the time 
of reappearance of T cells in the peripheral blood. 
Failure due to recurrent disease (mesangiocapillary 
glomerulonephritis and focal segmental glomerular scle- 
rosis) was observed in two of the patients, 1 and 2 months 
after transplantation, respectively. 
Discussion 
The results of our study indicate that prophylaxis with a 
single shot of r-ATG leads to acceptable results. Graft sur- 
vival was comparable to that in patients treated previously 
with either CyA or T-cell prophylaxis with h-ALG [6] or 
OKT3 [8]. After a single dose of r-ATG, we observed a 
low rate of acute rejection, lower than in patients treated 
with CyA alone. It must be stressed that our study was not 
performed prospectively, and therefore caution must be 
observed when interpreting the results. The incidence of 
primary nonfunction was the same in both groups. De- 
layed graft function tended to occur more frequently in 
the CyA group. An interesting observation in our study 
Table 2. Treatment outcome 
Patient group CyA-treated r-ATG-treated P value 
(n = 56) (n  = 58)  
~ 
CMVdTease 10(18%) 5 (8%) NS 
Urinary tract 
infections 22 (40 Yo ) 16 ( 2 8 % )  NS 
Primary nonfunction 19 (34%) 16 ( 2 8 % )  NS 
~ Never functioning 
grafts 5 (9%) 7(12%) NS 
- Delayed graft 
function 14(25%) 9 (15 yo) NS 
Acute rejection 
( < 3 months) 28 (50 Yo) 7 (12?'0) < 0.05 
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was the tendency towards a higher incidence of never 
functioning grafts due to thrombosis in the r-ATG group. 
This could be of special interest in light of a recent report 
by Abramowicz et al. [l]. They observed a 10% occur- 
rence of intragraft thrombosis within 2 weeks of trans- 
plantation following the administration of OKT3 at a dose 
of 10 mg/day. 
Following the administration of a single dose of r-ATG, 
T cells quickly disappeared from the circulation. It is inter- 
esting that the half-life of specific r-IgG was much shorter 
than that of total IgG. This could have been the result of 
clearance of specific IgG due to T-cell destruction [2]. 
These results demonstrate that the measurement of total 
circulating rabbit immunoglobulin overestimates the ef- 
fective plasma levels of r-ATG. Despite this rapid clear- 
ance of specific r-ATG, the number of circulating T cells 
remained low for 5-14 days, leading to an effective pro- 
phylactic period. Treatment with a single shot of r-ATG at 
a cost of $1500 was considerably cheaper than a 7-day 
course of either horse ALG or OKT3 at a cost of $4000 
each. 
We conclude that a single shot of r-ATG is an attrac- 
tive, easy, and cost-effective induction scheme with a low 
incidence of delayed graft function and acute rejection 
episodes. A relatively high incidence of vascular throm- 
bosis of the graft, however, warrants further study before 
this treatment regimen can be generally applied. 
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